期刊
MOVEMENT DISORDERS
卷 23, 期 13, 页码 1860-1866出版社
WILEY
DOI: 10.1002/mds.22169
关键词
Parkinson's disease; levodopa; dysminesia; NR2B subunit selective glutamate antagonist; CP-101.606; amnesia; dissociation
资金
- Pfizer Global Research and Development
- Oregon Clinical and Translational Research Institute [UL1-RR024140]
Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101.606 on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101.606 reduced the maximum severity of levodopa-induced dyskinesia similar to 30% but neither dose improved Parkinsonism. CP-101.606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. (C) 2008 Movement Disorder Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据